July 2023

Interested in learning about Generative AI for de novo drug design? Iktos hosted a webinar on ‘Where do we start if we don’t have any data? AI for early-stage projects …Read more

April 2023

Iktos announces the closing of a € 15.5m Series A financing to expand its artificial intelligence-based drug discovery technologies and solutions …Read more

January 2023

Peptides are a promising class of therapeutics with unique properties. They share some advantages of proteins, such as their high selectivity but also some of …Read more

October 2022

Our CSO, Dr. Quentin Perron and VP, Head of BD- EU, RoW Dr. Sree Vadlamudi presented a webinar on ‘Makya™ …Read more

August 2022

Take a tour of our new website and explore our AI-driven generative modeling technology platform …Read more

April 2022

We are very pleased to announce our 2nd Annual ‘AI for De Novo Drug Design’ Conference to be held virtually on May 3 and 4, 2022…Read more

January 2022

Our research paper on ‘Integrating synthetic accessibility with AI-based generative drug design’ was recently published by ChemRxiv…Read more

October 2021

We presented a webinar on ‘Spaya: Artificial Intelligence to discover and prioritise synthetic routes’. If you missed…Read more


Sign up to our newsletter

Quarterly circulation with latest technology developments, research collaborations, publications and other exciting updates

Iktos is a GDPR compliant organisation